NAD+ Science, Research & Development - NADclinic

Published Science Articles & References

NAD+ Reference (increasing energy, reducing free radicals, anti-ageing)

 

Alano CC, Garnier P, Ying W, Higashi Y, Kauppinen TM, and Swanson RA. NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci 30: 2967–2978, 2010 [ PMC free article] [ PubMed] [ Google Scholar]

Benfeitas R, Uhlen M, Nielsen J, and Mardinoglu A. New challenges to study heterogeneity in cancer redox metabolism. Front Cell Dev Biol 5: 65, 2017 [ PMC free article] [ PubMed] [ Google Scholar]

Braidy N, Guillemin G, and Grant R. Promotion of cellular NAD(+) anabolism: therapeutic potential for oxidative stress in ageing and Alzheimer's disease. Neurotox Res 13: 173–184, 2008 [ PubMed] [ Google Scholar]

Braidy N, Poljak A, Grant R, Jayasena T, Mansour H, Chan-Ling T, Guillemin GJ, Smythe G, and Sachdev P. Mapping NAD(+) metabolism in the brain of ageing Wistar rats: potential targets for influencing brain senescence. Biogerontology 15: 177–198, 2014 [ PubMed] [ Google Scholar]

Godoy JA, Rios JA, Zolezzi JM, Braidy N, and Inestrosa NC. Signalling pathway cross talk in Alzheimer's disease. Cell Commun Signal 12: 23, 2014 [ PMC free article] [ PubMed] [ Google Scholar]

Godoy JA, Zolezzi JM, Braidy N, and Inestrosa NC. Role of Sirt1 during the ageing process: relevance to protection of synapses in the brain. Mol Neurobiol 50: 744–756, 2014 [ PubMed] [ Google Scholar]

Marohnic CC, Bewley MC, and Barber MJ. Engineering and characterization of a NADPH-utilizing cytochrome b5 reductase. Biochemistry 42: 11170–11182, 2003 [ PubMed] [ Google Scholar]

Massudi H, Grant R, Guillemin GJ, and Braidy N. NAD+ metabolism and oxidative stress: the golden nucleotide on a crown of thorns. Redox Rep 17: 28–46, 2012 [ PMC free article] [ PubMed] [ Google Scholar]

Spaans SK, Weusthuis RA, van der Oost J, and Kengen SW. NADPH-generating systems in bacteria and archaea. Front Microbiol 6: 742, 2015 [ PMC free article] [ PubMed] [ Google Scholar]

Tang KS, Suh SW, Alano CC, Shao Z, Hunt WT, Swanson RA, and Anderson CM. Astrocytic poly(ADP-ribose) polymerase-1 activation leads to bioenergetic depletion and inhibition of glutamate uptake capacity. Glia 58: 446–457, 2010 [ PubMed] [ Google Scholar]

Tao R, Kim SH, Honbo N, Karliner JS, and Alano CC. Minocycline protects cardiac myocytes against simulated ischemia-reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1. J Cardiovasc Pharmacol 56: 659–668, 2010 [ PMC free article] [ PubMed] [ Google Scholar]

Warburg O. and Christian W. Pyridine, the hydrogen transferring element of fermentation enzymes (Pyridine-nucleotide.). Biochemische Zeitschrift 287: 291–328, 1936 [ Google Scholar]

Yin F, Boveris A, and Cadenas E. Mitochondrial energy metabolism and redox signaling in brain aging and neurodegeneration. Antioxid Redox Signal 20: 353–371, 2014 [ PMC free article] [ PubMed] [ Google Scholar]

Zeng J, Libien J, Shaik F, Wolk J, and Hernandez AI. Nucleolar PARP-1 expression is decreased in Alzheimer's disease: consequences for epigenetic regulation of rDNA and cognition. Neural Plast 2016: 8987928, 2016 [ PMC free article] [ PubMed] [ Google Scholar]

 

Clinical applications (in neurodegenerative diseases, cardiovascular risk factors, inflammatory conditions, hypoxic/chemotoxic damages, mental health)

 

Abeti R. and Duchen MR. Activation of PARP by oxidative stress induced by beta-amyloid: implications for Alzheimer's disease. Neurochem Res 37: 2589–2596, 2012 [ PubMed] [ Google Scholar]

Balu M, Mazhar A, Hayakawa CK, Mittal R, Krasieva TB, Konig K, Venugopalan V, and Tromberg BJ. In vivo multiphoton NADH fluorescence reveals depth-dependent keratinocyte metabolism in human skin. Biophys J 104: 258–267, 2013 [ PMC free article] [ PubMed] [ Google Scholar]

Braidy N, Grant R, Adams S, and Guillemin GJ. Neuroprotective effects of naturally occurring polyphenols on quinolinic acid-induced excitotoxicity in human neurons. FEBS J 277: 368–382, 2010 [ PubMed] [ Google Scholar]

Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, Leo O, So A, and De Smedt T. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 3: e2267, 2008 [ PMC free article] [ PubMed] [ Google Scholar]

Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, Fernandez-Marcos PJ, Yamamoto H, Andreux PA, Cettour-Rose P, Gademann K, Rinsch C, Schoonjans K, Sauve AA, and Auwerx J. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 15: 838–847, 2012 [ PMC free article] [ PubMed] [ Google Scholar]

Diamond MP, Fletcher NM, Neubauer BR, Saed MG, H M AS, and Saed GM. Hypoxia-induced genotype switch in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase through the up-regulation of cytidine deaminase regulates postoperative adhesion development. J Minim Invasive Gynecol 22: S159, 2015 [ PubMed] [ Google Scholar]

Gensler HL. Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamide. Nutr Cancer 29: 157–162, 1997 [ PubMed] [ Google Scholar]

Grant RS. and Kapoor V. Murine glial cells regenerate NAD, after peroxide-induced depletion, using either nicotinic acid, nicotinamide, or quinolinic acid as substrates. J Neurochem 70: 1759–1763, 1998 [ PubMed] [ Google Scholar]

Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 18: 415–420, 2007 [ PubMed] [ Google Scholar]

Hershberger KA, Martin AS, and Hirschey MD. Role of NAD(+) and mitochondrial sirtuins in cardiac and renal diseases. Nat Rev Nephrol 13: 213–225, 2017 [ PMC free article] [ PubMed] [ Google Scholar]

Lehmann S, Costa AC, Celardo I, Loh SH, and Martins LM. PARP mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson's disease. Cell Death Dis 7: e2166, 2016 [ PMC free article] [ PubMed] [ Google Scholar]

Martire S, Fuso A, Mosca L, Forte E, Correani V, Fontana M, Scarpa S, Maras B, and d'Erme M. Bioenergetic impairment in animal and cellular models of Alzheimer's disease: PARP-1 inhibition rescues metabolic dysfunctions. J Alzheimers Dis 54: 307–324, 2016 [ PubMed] [ Google Scholar]

Martire S, Mosca L, and d'Erme M. PARP-1 involvement in neurodegeneration: a focus on Alzheimer's and Parkinson's diseases. Mech Ageing Dev 146–148: 53–64, 2015 [ PubMed] [ Google Scholar]

Oblong JE. The evolving role of the NAD+/nicotinamide metabolome in skin homeostasis, cellular bioenergetics, and aging. DNA Repair (Amst) 23: 59–63, 2014 [ PubMed] [ Google Scholar]

Shetty PK, Galeffi F, and Turner DA. Nicotinamide pre-treatment ameliorates NAD(H) hyperoxidation and improves neuronal function after severe hypoxia. Neurobiol Dis 62: 469–478, 2014 [ PMC free article] [ PubMed] [ Google Scholar]

Shi H, Sun N, Mayevsky A, Zhang Z, and Luo Q. Preclinical evidence of mitochondrial nicotinamide adenine dinucleotide as an effective alarm parameter under hypoxia. J Biomed Opt 19: 17005, 2014 [ PubMed] [ Google Scholar]

Soudijn W, van Wijngaarden I, and Ijzerman AP. Nicotinic acid receptor subtypes and their ligands. Med Res Rev 27: 417–433, 2007 [ PubMed] [ Google Scholar]

Surjana D, Halliday GM, Martin AJ, Moloney FJ, and Damian DL. Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol 132: 1497–1500, 2012 [ PubMed] [ Google Scholar]

Tanno O, Ota Y, Kitamura N, Katsube T, and Inoue S. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol 143: 524–531, 2000 [ PubMed] [ Google Scholar]

Tong DL, Zhang DX, Xiang F, Teng M, Jiang XP, Hou JM, Zhang Q, and Huang YS. Nicotinamide pretreatment protects cardiomyocytes against hypoxia-induced cell death by improving mitochondrial stress. Pharmacology 90: 11–18, 2012 [ PubMed] [ Google Scholar]

Turunc Bayrakdar E, Uyanikgil Y, Kanit L, Koylu E, and Yalcin A. Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Abeta(1–42)-induced rat model of Alzheimer's disease. Free Radic Res 48: 146–158, 2014 [ PubMed] [ Google Scholar]

Vaccari CS, Nagamia S, Thoenes M, Oguchi A, Hammoud R, and Khan BV. Efficacy of controlled-release niacin in treatment of metabolic syndrome: correlation to surrogate markers of atherosclerosis, vascular reactivity, and inflammation. J Clin Lipidol 1: 605–613, 2007 [ PubMed] [ Google Scholar]

Wang H, Liang X, Luo G, Ding M, and Liang Q. Protection effect of nicotinamide on cardiomyoblast hypoxia/re-oxygenation injury: study of cellular mitochondrial metabolism. Mol Biosyst 12: 2257–2264, 2016 [ PubMed] [ Google Scholar]

Wang P, Du H, Zhang RY, Guan YF, Xu TY, Xu QY, Su DF, and Miao CY. Circulating and local visfatin/Nampt/PBEF levels in spontaneously hypertensive rats, stroke-prone spontaneously hypertensive rats and Wistar-Kyoto rats. J Physiol Sci 60: 317–324, 2010 [ PubMed] [ Google Scholar]

Wang P. and Miao CY. NAMPT as a therapeutic target against stroke. Trends Pharmacol Sci 36: 891–905, 2015 [ PubMed] [ Google Scholar]

Wang X, Hu X, Yang Y, Takata T, and Sakurai T. Nicotinamide mononucleotide protects against beta-amyloid oligomer-induced cognitive impairment and neuronal death. Brain Res 1643: 1–9, 2016 [ PubMed] [ Google Scholar]

Wei CC, Kong YY, Li GQ, Guan YF, Wang P, and Miao CY. Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2/HO-1 signaling pathway. Sci Rep 7: 717, 2017 [ PMC free article] [ PubMed] [ Google Scholar]

NADclinic Ltd © 2022 | Company Number: 11468735 | Medical Director Prof. Dr. Med. P. Shoettle GMC Reg - 7622265

Your bag

Subtotal